Evidence map›Paper›PMID 40182128›Full record

ArticleCancer pathogenesis and therapy2025

Breast cancer risk associated with

Sanjian Yu, Xia Qiu, Zezhou Wang, Jialong Xiao, Hui Ji, Hailin Shan, Qing Shao, Heng Xia, Feng Cao, Jun Li and 11 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer pathogenesis and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04265937 (Screening of Genetic Susceptibility Genes for Breast Cancer Patients and Establishment of High-risk Populations in Chinese Communities), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04265937 unknown statusnot on this map

Screening of Genetic Susceptibility Genes for Breast Cancer Patients and Establishment of High-risk Populations in Chinese Communities

TypeobservationalSponsorFudan UniversityRan2019 to 2026Enrolled5,000ConditionsBreast Cancer, Genetic Susceptibility
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy.International journal of molecular sciences · 2025
    Review
  4. Connecting scientists and oncologists for advances.Cancer pathogenesis and therapy · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sanjian YuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xia QiuDepartment of Breast Surgery, Zhoushan Hospital, Zhoushan, Zhejiang 31600, China.
Zezhou WangDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Jialong XiaoDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Hui JiDepartment of General Surgery, Shanghai Tenth People's Hospital, Chongming Branch, Shanghai 202157, China.
Hailin ShanDepartment of Thyroid and Breast Surgery, Jiangyin People's Hospital, Southeast University, Jiangyin, Jiangsu 214499, China.
Qing ShaoDepartment of Thyroid and Breast Surgery, Jiangyin People's Hospital, Southeast University, Jiangyin, Jiangsu 214499, China.
Heng XiaDepartment of Thyroid and Breast Surgery, Shaoxing Central Hospital, Shaoxing, Zhejiang 312030, China.
Feng CaoDepartment of General Surgery, Shanghai Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China.
Jun LiDepartment of General Surgery, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, China.
Cuixia FuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Liqin ChenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Xiaofang LuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Tingting SuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Qianqian YuDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Shengqun HouDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Honglian WangAITA Biomedical Research Institute, Shanghai 201101, China.
Ying ZhengDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Zhimin ShaoDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yun LiuDepartment of Biliary and Pancreatic Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Zhen HuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Population-based penetrance studies of breast cancer gene 1/2 ( Methods: Between July 2019 and March 2021, we tested 2216 breast cancer probands from Chinese communities for Results: Of the 2216 breast cancer probands, 109 (4.90%) carried Conclusions: Our findings showed that breast cancer penetrance among Trial registration: ClinicalTrials.gov; https://clinicaltrials.gov/ct2/show/NCT04265937.

Indexed as

BRCA1/2 gene mutationsBreast cancerChinese populationPopulation-based studies

Identifiers

PMID40182128
PMCPMC11963186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.